HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Claritin Hypospadia Review Targeted For Summer Completion

This article was originally published in The Tan Sheet

Executive Summary

FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months

You may also be interested in...



Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports

Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said

Claritin and hypospadia

FDA review of possible link between loratadine and birth defects "unlikely" to impact its decision on Schering-Plough's NDAs to switch Claritin OTC, agency says, noting many non-Rx products carry labeling restrictions concerning use during pregnancy. In addition to internal review being conducted by Division of Pulmonary & Allergy Drug Products and Office of Drug Safety, agency is consulting with outside experts in review of Swedish data, other information. FDA analysis, which extends to data for Rx Clarinex (desloratadine), could be completed by late September. Separate review by European Agency for the Evaluation of Medicinal Products is ongoing (1"The Tan Sheet" May 6, 2002, p. 3)...

Allegra Asthma Claim Would Be Key Defense Vs. Forced OTC Switch – Aventis

Aventis' Allegra experimental asthma indication would be the best defense against a forced OTC switch of the antihistamine, Chief Operating Officer Richard Markham told analysts during Aventis' R&D day in London June 18

Related Content

Topics

UsernamePublicRestriction

Register

PS142249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel